30 September 2024 - interim results
The AIM-listed pharmaceutical group has announced its interim results for the six months to 30 June with revenues up 2.8% to £84.8m as previously reported. Underlying pre-tax profits rose by 23.3% to £12.7m with earnings per share on the same basis some 13.9% higher at 1.80p. These results have benefited from strong growth in the Kelo-Cote scar prevention and treatment franchise which more than made up for disappointing sales of both Nizoral and Amberen where sales declined. Strong cash flow during the period allowed net debt . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
